Tasigna, generically known as nilotinib, is a prescription medication used in the treatment of certain types of chronic myeloid leukemia (CML), a form of cancer that affects the white blood cells. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), which work by blocking the action of a specific enzyme, tyrosine kinase, that's responsible for the uncontrolled growth of cancer cells. By inhibiting this enzyme, Tasigna helps to slow down or stop the proliferation of cancer cells. It is specifically used in patients who have newly diagnosed CML or those who are resistant to or cannot tolerate other TKIs such as imatinib. Tasigna is taken orally in capsule form and its use requires careful monitoring by a healthcare provider due to potential side effects and interactions with other medications.